Background. Pseudomonas aeruginosa is a common cause of healthcare-associated infection. Multidrug-resistant (MDR) (>3 classes) and carbapenem-resistant (CR) P aeruginosa are significant threats globally. We used a large reference-laboratory database to study the epidemiology of P aeruginosa in children in the United States.
Pseudomonas aeruginosa is a Gram-negative bacterium that causes infections that can lead to significant morbidity and death. It is a complex and formidable adversary that has great genetic "plasticity, " which facilitates development of antibiotic-resistance mutations, and striking survival rates in the most diverse environments because of its minimal nutritional requirements and ability to use a variety of carbon sources for energy [1] . The severity of such infections is attributable to the broad range of virulence factors carried by the bacterium, including the type III secretion system, which helps establish infection by injecting effector proteins into host cells and thereby enhancing disease severity [2, 3] .
Potentially even more multifaceted are the mechanisms of antibiotic resistance attributed to P aeruginosa. Foremost have been enzymes that are able to inactivate β-lactam antibiotics; these intrinsic and acquired β-lactamases include cephalosporinases (which produce extended-spectrum cephalosporin resistance) and carbapenemases (which produce carbapenem resistance). Additional resistance mechanisms rely on enzymatic and target-site modifications (aminoglycoside and fluoroquinolone resistance), alterations in outer membrane permeability, and multidrug efflux pumps. The latter 2 mechanisms often render organisms multidrug resistant (MDR) and leave few treatment options against them [4] . The US Centers for Disease Control and Prevention estimates that each year, 51 000 healthcare-associated P aeruginosa infections occur in adults and children, of which 13% (>6000) are MDR and account for 400 deaths [5] .
Infections with P aeruginosa in children are reported most often in association with pulmonary disease in patients with cystic fibrosis (CF) [6] . In addition, healthy children can experience a variety of P aeruginosa infection types, particularly infection of the urinary tract, ear, sinuses, wounds, skin, and connective tissues (cartilage and bone) [7] [8] [9] [10] [11] [12] . However, as in adults, serious and systemic, often opportunistic, infections are substantial in children with critical illness, in those who require ventilator support, and in patients who are immunocompromised and/or have a hematologic-oncologic disease [7, 8, [13] [14] [15] [16] [17] [18] .
The majority of P aeruginosa studies have examined the effect of these infections on patients with CF. Despite the annual numbers of infection and rising rates of antibiotic resistance, no pediatric studies have assessed national or regional trends in MDR or carbapenem-resistant (CR) P aeruginosa. In this study, we investigated the epidemiology of P aeruginosa isolates from children, excluding those with CF, and explored trends in antibiotic resistance over a period of 13.5 years.
METHODS
Antibiotic-susceptibility data were obtained from the Surveillance Network (TSN) Database-USA (Eurofin-Medinet, Herndon, VA). The database has been used extensively to characterize national antibiotic-susceptibility trends [19] [20] [21] [22] . The network included clinical microbiology laboratories that served approximately 300 hospitals that were selected by the 9 US Census Bureau regional divisions to be geographically representative and representative of hospital size and patient population. Laboratories included in the TSN database were required to submit results from all routine antimicrobial-susceptibility testing performed on site. Categorical result interpretations were based on Clinical Laboratory Standards Institute (CLSI) criteria adopted by the reporting facilities at the time of testing and reflect susceptibilities as reported to clinicians [23] . Individual laboratory data were validated electronically and merged into a central TSN database.
The database includes records with the following information: the identified organism; the tested drug and susceptibility result (susceptible, intermediate-resistant, or resistant); the source of the isolate (blood, urine, wound, respiratory tract, or skin); patient characteristics (age and sex); the healthcare setting in which the patient sample was collected (outpatient [ambulatory] , inpatient intensive care unit [ICU] , inpatient [non-ICU], or long-term care setting); the geographical location of the facility in which the specimen was collected; and the date of the drug-susceptibility test.
Our analysis considered P aeruginosa isolates obtained from all pediatric patients (aged 1-17) who were in an outpatient (ambulatory), inpatient ICU, inpatient non-ICU, or long-term care setting between January 1, 1999, and June 30, 2012. To improve applicability to the general pediatric population, isolates from patients with CF were excluded from the analysis. We also excluded isolates obtained from patients <1 year old, because the epidemiology of MDR and CR P aeruginosa in neonates (in particular, infants cared for in the neonatal ICU) likely differs from that in older children and should be analyzed separately. MDR P aeruginosa was defined using US Centers for Disease Control and Prevention criteria [24] , which included nonsusceptibility to agent(s) in at least 3 of the following 5 antimicrobial classes: cephalosporins (cefepime, ceftazidime), β-lactam/β-lactamase-inhibitor combination (piperacillin, piperacillin-tazobactam), carbapenems (imipenem, meropenem, doripenem), fluoroquinolones (ciprofloxacin, levofloxacin), and aminoglycosides (gentamicin, tobramycin, amikacin). An isolate was deemed CR P aeruginosa if it was nonsusceptible to at least 1 of the 3 agents in the carbapenem class (imipenem, meropenem, or doripenem). Only isolates that were tested for all 5 antibiotic classes, including carbapenems, were included in the final analysis.
When duplicate records (with the same patient identification number, drug-susceptibility test, and specimen source) were identified, only the first isolate was included in the analysis. The frequency of MDR and CR P aeruginosa is reported as the number of isolates that tested positive divided by the total number of tested isolates included in the analysis. Individual susceptibility results were stratified according to location (ICU, inpatient non-ICU, outpatient, and long-term care facilities), age (1-5, 6-12, and 13-17 years), sex, isolate source (blood, urine, wound, respiratory tract, and skin), annual intervals, and geographic region based on the location of the healthcare facility (East North Central, East South Central, Mid-Atlantic, Mountain, New England, Pacific, South Atlantic, West North Central, and West South Central). Because the antibiotic-susceptibility patterns differed among hospitalized and nonhospitalized patients, we examined the distributions of MDR and CR P aeruginosa isolates among those obtained from patients in inpatient (ICU or inpatient non-ICU) and outpatient (ambulatory) facilities. In addition, we examined the susceptibility of P aeruginosa isolates to all agents in each of the 5 antibiotic classes among the inpatients and outpatients.
Unadjusted trends in the prevalences of MDR and CR P aeruginosa were calculated using logistic regression. Multivariable logistic regression analysis was used to estimate the prevalences of MDR and CR P aeruginosa, which was adjusted for time (year) and patient characteristics, including age, sex, isolate source, patient location, and geographic region. Confidence intervals (CIs) were calculated using a Wilson score method. A P value of <.05 was considered statistically significant. Data were analyzed using the R programming language.
RESULTS
Overall, 87 613 pediatric P aeruginosa isolates were identified in the database between 1999 and 2012, of which 77 349 isolates were tested against 5 antibiotic classes, including carbapenems. Of these 77 349 P aeruginosa isolates, 15 653 (20.2%) isolates were MDR, 8763 (11.3%) were CR, and 6510 (8.4%) were both MDR and CR. Overall, the isolates were most often from outpatients (44 158 (Table 1) .
Overall, among the various patient and isolate characteristics, the proportion of MDR and CR P aeruginosa isolates was higher in inpatients than in outpatients (Table 2) Table 2 ).
An analysis of linear trends using logistic regression revealed a significant increase in the proportion of both MDR (15.4%-26.0%; P < .001) and CR (9.4%-20.0%; P < .001) P aeruginosa isolates between 1999 and 2012 ( Figure 1 Table 1 ). After the data were adjusted for year, patient, and isolate characteristics, patients who were 13 to 17 years old had the highest prevalences of MDR and CR P aeruginosa, which were 3 times (adjusted ORs [aORs], 3.0 [95% CI, 2.8-3.1]) and 2 times (aOR, 1.96 [95% CI, 1.8-2.0]) higher than those in 1-to 5-year-old children (Table 3) . Among patient locations, long-term care residents had the highest prevalence of MDR P aeruginosa, 2.3 times (aOR, 2.3 [95% CI, 1.8-2.9]) higher than that in the outpatient locations, whereas the CR P aeruginosa prevalence was highest in ICUs, 2.6 times (95% CI, 2.4-2.8] higher than that in outpatient locations (Table 3) . Among specimen sources, respiratory specimens had the highest prevalences of MDR and CR P aeruginosa, 1.8 times (aOR, 1.8 [95% CI, 1.6-2.1]) and 1.2 times (aOR, 1.2 [95% CI, 1.0-1.3]) higher than that of specimens obtained from blood. Among the geographic regions, MDR and CR P aeruginosa isolates were most prevalent in the West North Central Region, 1.8 times (aOR, 1.8 [95% CI, 1.7-1.9]) and 1.5 times (aOR, 1.5 [95% CI, 1.3-1.6]) higher than that in the East North Central region of United States.
P aeruginosa resistance to other frequently used antibiotic classes was higher among inpatient isolates than among outpatient isolates with the exception of aminoglycosides (amikacin, gentamicin, and tobramycin) ( Table 4 and Supplementary (Table 4) .
DISCUSSION
We observed significant increases in the prevalences of MDR and CR P aeruginosa isolates from US children between 1999 and 2012. Children admitted to an ICU, with a respiratory tract infection, between the ages of 13 and 17 years, and in the West North Central region of the United States had higher prevalences of MDR and CR P aeruginosa. Although the prevalence of MDR P aeruginosa in long-term care settings was highest, overall, there were not enough isolates from this setting in our data set to derive a robust conclusion. Antibiotic resistance in P aeruginosa, arguably the most resistance-prone healthcare pathogen, is not a new phenomenon; however, antibiotic-resistant infections continue to become more complex and difficult to treat and are associated with significant hospital and societal costs [25] . P aeruginosa has a unique ability to survive in harsh environments; mechanisms that protect this bacterium from the actions of antibiotics include intrinsic resistance associated with chromosomally encoded β-lactamase enzymes; quorum-sensing proteins that let the bacteria communicate, which facilitates the formation of protective biofilms; efflux pumps that remove threats from the bacterial cytoplasm; structural topoisomerase mutations that deactivate fluoroquinolones; and cell wall porin alterations and outer membrane changes that prevent entry of antibiotics or other threats to bacterial survival and that work in concert to prevent antibiotics from eradicating it [4, 26] . The acquisition of mobile genetic elements, such as plasmids and transposons that harbor genes encoding for carbapenemases, aminoglycoside-modifying enzymes, and fluoroquinolone resistance determinants, contribute to high levels of resistance to last-line antibiotics such as the carbapenems, (imipenem, meropenem, and doripenem) and to the expression of MDR phenotypes among isolates [4, 27, 28] . Because ICUs harbor critically ill and immunocompromised children and involve high antibiotic and device usage rates, it is not surprising that we found high prevalences of MDR and CR P aeruginosa isolates in ICU patients [29] . High prevalences of MDR and CR P aeruginosa isolates among older children might relate to an increasing number of children with a medically complex condition who have frequent exposure to the healthcare environment [30] .
With increasing drug resistance, the antibiotics used for effective treatment have expanded, and the selection pressure for the MDR and CR phenotypes continues to grow; institutional pan-drug-resistant P aeruginosa outbreaks in the United States have been described [31] . Colonization of P aeruginosa is associated with a polyclonal endemicity in hospitalized patients [32] , and for decades, traditional infection-control practices have failed to control it [33] . The ubiquitous presence of P aeruginosa in the environment, water sources, and healthcare settings has prevented control of its acquisition among our most vulnerable patients, including critically ill patients, Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; CR, carbapenem resistant; ICU, intensive care unit; MDR, multidrug resistant. *Sex was not considered, because no significant differences in the distributions of isolates between male and female patients were found.
burn victims, immunocompromised patients, and children [29, 34, 35] . However, there have been notable infection-control successes in decreasing organism burdens, particularly with regard to catheter-associated infections [36, 37] . P aeruginosa is a common cause of catheter-associated urinary tract infection (CAUTI) and is associated with the formation of antibioticresistant biofilms and subsequent risk for severe infections such as bacteremia [38] . National efforts to reduce CAUTIs through detection and prevention programs include a multifaceted approach that involves provider education, microbial surveillance, performance measures, and bundled interventions; successful program implementations have been associated with improved patient outcomes [36, 37] . The increase in MDR P aeruginosa strains in children during the study period also might relate to trends in antibiotic-prescribing practices in the United States. Between 2000 and 2010, prescriptions of third-and fourth-generation cephalosporins and other broad-spectrum agents, including fluoroquinolones, increased in children in outpatient settings [39, 40] . Similarly, recent antibiotic-prescribing data from inpatient studies revealed similar findings, indicating increased selection pressure for colonization with MDR strains [41] . High prevalences of MDR and CR P aeruginosa isolates in the West North Central region might be associated with the reported high antibiotic consumption in this region [42, 43] . The highest rates of other MDR Gram-negative bacilli in children, such as CR Enterobacteriaceae, were reported in this region also [21] .
Antimicrobial stewardship programs, which improve prescribing practices and restrict the use of broad-spectrum antimicrobial agents, have been shown to be highly effective in decreasing the incidence of healthcare-acquired infections, including infection with P aeruginosa [44] A 22-hospital survey found that restriction of carbapenem use was successful in reducing the incidence rates of CR P aeruginosa over a 5-year period in adult and pediatric patients [38] . A meta-analysis of MDR infections suggested substantial links to antibiotic usage, and improved antibiotic-prescribing practices resulted in reductions in antibiotic-resistant pathogens [45] . These best practices for decreasing antibiotic consumption have been substantiated in pediatrics and in critical care units, which is relevant to our findings of the most dramatic uptrends occurring in young children and those cared for in an intensive care setting [46, 47] .
The importance of these initiatives is underscored not only in our findings of increasing MDR and CR P aeruginosa isolates but also in the notable increases in resistance to other commonly used therapies, including cefepime, piperacillin-tazobactam, fluoroquinolones (ciprofloxacin and levofloxacin), and aminoglycosides (gentamicin, tobramycin, and amikacin). The high rates of fluoroquinolone resistance in P aeruginosa related to the widespread use of this agent (associated with the availability of oral and intravenous formulations) have been well described in adult study reports [48] ; however, before this study, fluoroquinolone-resistant P aeruginosa was described recently as having a low prevalence in US children, except in patients with CF [49, 50] . Similarly, the findings of high levels of gentamicin resistance in inpatient and outpatient settings might be reflective of the multiple modes of delivery, including topical, inhalation, and intravenous formulations, available to children. Colonization with gentamicin-resistant organisms has been associated with all formulations, including topical formulations [51, 52] .
Increasing trends in P aeruginosa resistance to various antibiotics in ambulatory settings might reflect improvements in outpatient therapeutic approaches for patients who previously required hospitalization (such as in the care of children with neutropenic cancer or in ventilator-dependent children) [53, 54] , or alternatively, notable practices of prescribing long-term prophylactic antibiotics and multiple oral treatment courses for children with recurrent urinary tract infections and/or urinary tract abnormalities [55, 56] . The significant number of tracheal aspirates (~12%) obtained from patients in an outpatient setting (Supplementary Table 3) suggests that, in recent decades, more children with a chronic respiratory disease and/ or a tracheostomy are being managed at home with ventilator support rather than in a long-term care facility and that these children are often monitored in ambulatory ventilator or pulmonology clinics. However, the frequent need for hospitalization, concern about morbidity and death that result from sepsis, and subsequent exposure to broad-spectrum intravenous antibiotics remains a burden for all of these children [15, 57, 58] . Revolutionary advances in rapid molecular diagnostics for viral and bacterial pathogens are assisting in the identification of patients who might more definitively benefit from antimicrobial therapy and those for whom antibiotics are not indicated [59] [60] [61] .
Our study has important limitations. First, because the data stemmed from laboratory surveillance, we were not able to distinguish between colonization and true infection, and we could not account for detailed clinical characteristics of the individual patients. Second, as is common with large databases, some uncertainty was introduced by coding discrepancies, as for cases in which patients were treated in a location other than that recorded at admission. Third, although all TSN laboratories apply CLSI methods, minimum inhibitory concentrations (MICs) were not available, and susceptibility testing was not centralized, which introduced some margin of uncertainty as a result of local discrepancies. Fourth, there was a reduction in the number of laboratories that reported data in the final years of the study, which might have affected variations in carbapenem and multidrug resistance; however, the increasing trends and high levels of statistical significance found throughout the study period lessen this concern. Fifth, we do not have more recent data (beyond 2012), because the TSN database was disbanded after 2012; however, these are the only national-level trend data available. Sixth, CLSI breakpoints for piperacillin-tazobactam were lowered in January 2012 [62] , which might have contributed to the higher MDR rates in 2012; however, a sensitivity analysis in which the year 2012 was excluded still showed a significant increase in MDR P aeruginosa trends. Seventh, we included only isolates that were tested against all 5 classes of antibiotics. Although the distribution of excluded isolates according to patient and isolate characteristics was similar to that of the included isolates (Supplementary Table 4) , there is a possibility of both underestimation and overestimation of MDR isolates with exclusion of these isolates. Finally, the observed increases in the rates of MDR and CR P aeruginosa over time might partly be a result of clinicians becoming more discerning about which patients to test.
CONCLUSIONS
Infection with MDR or CR P aeruginosa is a significant threat to all patients, including children. The results of our study highlight the need for bacterial surveillance, strategies for implementing effective infection-prevention, and antimicrobial stewardship programs. The institution of rapid molecular diagnostic platforms should be considered by all healthcare facilities to guide antibiotic treatment decisions in an effort to reduce the burden of the persistent and continually evolving global threat of extensively drug-resistant organisms.
